Alumis Inc. Announces Envudeucitinib Long-Term Data

What Happened Alumis Inc. filed a Current Report on Form 8-K on August 10, 2026 (Item 8.01) to announce a press release titled “Envudeucitinib Long-Term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies.” The press release, which the company incorporated by reference into the 8-K as Exhibit 99.1, highlights long‑term clinical data for Envudeucitinib in plaque psoriasis and asserts the highest reported PASI 100 (complete skin clearance) among oral therapies.

Key Details

• Filing date: August 10, 2026 (Form 8-K, Item 8.01).
• Press release title: “Envudeucitinib Long-Term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies.”
• Product: Envudeucitinib (investigational treatment for plaque psoriasis).
• Exhibit: Press release filed as Exhibit 99.1 and incorporated by reference.

Why It Matters This 8-K notifies investors that Alumis is publicly promoting long‑term efficacy data for Envudeucitinib and is positioning those results as potentially differentiated among oral psoriasis treatments (claiming the highest reported PASI 100). The filing is a disclosure of clinical results and messaging; it does not itself report financial results, regulatory approvals, or changes in management. Investors should review the press release and any supporting clinical data for details before drawing conclusions about commercial or regulatory impact.